On Wednesday, October 22, 2025, Moderna announced that it would discontinue development of its experimental cytomegalovirus (CMV) vaccine, mRNA‑1647, after the vaccine failed to meet the primary efficacy endpoint in a late‑stage Phase 3 trial.
The company stated that it will continue to evaluate mRNA‑1647 in an ongoing Phase 2 study of bone‑marrow transplant patients, but the failure in the Phase 3 trial means the product will no longer enter the market. Moderna also said the discontinuation would not affect its 2025 financial guidance or its target for cash breakeven in 2028.
The CMV vaccine represented a potential revenue source for Moderna’s post‑COVID portfolio, but the decision removes that opportunity from the pipeline. While the immediate financial impact is limited, the move signals a tightening of the company’s focus on higher‑probability candidates and may influence investor expectations about future product launches.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.